Cellectis (CLLS) Lifted to Buy at ValuEngine

Cellectis (NASDAQ:CLLS) was upgraded by ValuEngine from a “hold” rating to a “buy” rating in a research note issued to investors on Monday.

Other research analysts have also issued research reports about the stock. BidaskClub upgraded shares of Cellectis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 17th. Zacks Investment Research lowered shares of Cellectis from a “hold” rating to a “sell” rating in a research report on Wednesday, February 14th. Guggenheim assumed coverage on shares of Cellectis in a research report on Friday, March 16th. They issued a “neutral” rating on the stock. Nomura lifted their price target on shares of Cellectis to $73.00 and gave the stock a “buy” rating in a research report on Wednesday, March 14th. Finally, Oppenheimer restated an “outperform” rating and issued a $40.00 price target on shares of Cellectis in a research report on Thursday, December 28th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $42.67.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ CLLS traded down $0.78 during mid-day trading on Monday, reaching $30.73. 108,445 shares of the company traded hands, compared to its average volume of 186,717. Cellectis has a fifty-two week low of $21.25 and a fifty-two week high of $36.13. The firm has a market capitalization of $1,132.10, a PE ratio of -11.05 and a beta of 1.85.

Cellectis (NASDAQ:CLLS) last posted its quarterly earnings data on Monday, March 12th. The biotechnology company reported ($0.76) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.64) by ($0.12). The company had revenue of $6.91 million for the quarter, compared to analyst estimates of $10.10 million. Cellectis had a negative net margin of 298.01% and a negative return on equity of 35.63%. analysts forecast that Cellectis will post -2.62 EPS for the current year.

A number of institutional investors have recently bought and sold shares of the business. Perceptive Advisors LLC acquired a new position in Cellectis in the 4th quarter worth approximately $10,203,000. BlackRock Inc. acquired a new position in Cellectis in the 4th quarter worth approximately $4,422,000. Millennium Management LLC boosted its stake in Cellectis by 1,356.2% in the 4th quarter. Millennium Management LLC now owns 104,290 shares of the biotechnology company’s stock worth $3,040,000 after purchasing an additional 97,128 shares during the period. Bain Capital Public Equity Management LLC acquired a new position in Cellectis in the 4th quarter worth approximately $2,848,000. Finally, Granite Point Capital Management L.P. acquired a new position in Cellectis in the 4th quarter worth approximately $1,458,000. Hedge funds and other institutional investors own 20.31% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Cellectis (CLLS) Lifted to Buy at ValuEngine” was first posted by WKRB News and is the property of of WKRB News. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.wkrb13.com/2018/04/03/cellectis-clls-lifted-to-buy-at-valuengine.html.

Cellectis Company Profile

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.

Analyst Recommendations for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply